Effect Analysis of Combination Therapy of Ulinastatin and Thymosin α1 in Treatment of Septic Shock with Acute Kidney Injury
Objective The paper mainly studies patients with sepsis shock combined with acute kidney injury,analyzes clinical effect of combination therapy of ulinastatin and thymosin α1,and improve symptoms of patients. Methods The paper chose 56 patients with septic shock complicated with acute kidney injury in our hospital from January 2021 to January 2023 as experimental study subjects,and divided them into the single group (28 cases) and the combination group (28 cases) according to their voluntary wishes,treated with ulinastatin and ulinastatin combined with thymosin α1 respectively. The improvement rate of symptoms,inflammatory factor indicators,and life quality indicators were compared between two groups. Results There was significant difference in improvement rate between two groups of symptoms (P＜0.05),with improvement rates of 71.43％ and 96.43％ respectively. Before treatment,there was no significant difference in inflammatory cytokine indicators of patients (P＞0.05). After treatment,the combination group had more ideal control effect (P＜0.05). Before treatment,there was no significant difference in life quality of patients (P＞0.05). After treatment,the improvement effect of the combination group was more ideal (P＜0.05),which could improve mental state,physiological state,physical function,and pain level of patients effectively. Conclusion Ulinastatin combined with thymosin α1 can improve symptoms,reduce inflammatory reactions effectively,and improve life quality of septic shock patients with acute kidney injury during clinical application,can provide patients with good living condition,with high treatment satisfaction,and promote the harmonious development of doctor-patient relationships.
万方数据
维普
